Breaking News Instant updates and real-time market news.

RDS.A

Royal Dutch Shell

$63.82

0.26 (0.41%)

, RDS.B

Royal Dutch Shell

$64.78

0.33 (0.51%)

10:20
05/13/19
05/13
10:20
05/13/19
10:20

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Royal Dutch Shell (RDS.A, RDS.B) upgraded to Buy from Hold at Deutsche Bank and HSBC. 2. KB Home (KBH) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying his firm's spring agent survey confirmed that housing fundamentals have improved and stabilized. 3. Becton Dickinson (BDX) upgraded to Overweight from Equal Weight at Barclays with analyst Kristen Stewart saying the pullback in the shares since the FDA update on drug-coated balloons on March 15, coupled with the resetting of expectations following the company's Q2 results, provides an opportunity for investors. 4. Merck (MRK) upgraded to Overweight from Neutral at Atlantic Equities. 5. Bausch Health (BHC) upgraded to Neutral from Underweight at JPMorgan with analyst Chris Schott saying while a number of challenges remain in the story given the company's high leverage and controversial Xifaxan loss of exclusivity, its EBITDA is "clearly stabilizing and should begin to grow from here." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

RDS.A

Royal Dutch Shell

$63.82

0.26 (0.41%)

RDS.B

Royal Dutch Shell

$64.78

0.33 (0.51%)

KBH

KB Home

$26.00

-0.145 (-0.55%)

BDX

Becton Dickinson

$224.70

-0.63 (-0.28%)

MRK

Merck

$77.21

-1.02 (-1.30%)

BHC

Bausch Health

$24.85

-0.45 (-1.78%)

  • 18

    May

  • 20

    May

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 17

    Jun

  • 20

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 20

    Sep

RDS.A Royal Dutch Shell
$63.82

0.26 (0.41%)

05/13/19
DBAB
05/13/19
UPGRADE
DBAB
Buy
Royal Dutch Shell upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Royal Dutch Shell to Buy from Hold with a price target of 2700 pence.
05/13/19
HSBC
05/13/19
UPGRADE
HSBC
Buy
Royal Dutch Shell upgraded to Buy from Hold at HSBC
HSBC analyst Gordon Gray upgraded Royal Dutch Shell (RDS.A) to Buy from Hold. The analyst believes the global integrated oil sector is attractive following the recent selloff in the shares. With free cash break-evens in the low-$50s per barrel oil price, the majors are positioned for a period of sustained excess free cash flow and strong cash distributions, Gray tells investors in a research note. Deutsche Bank this morning also upgraded Royal Dutch Shell to Buy. Gray coupled his upgrade with a downgrade of Exxon Mobil (XOM) to Hold from Buy. He says Exxon's cash generation has been relatively weak.
05/09/19
MSCO
05/09/19
UPGRADE
MSCO
Equal Weight
Shell upgraded to Equal Weight ahead of expected dividend hike at Morgan Stanley
As previously reported, Morgan Stanley analyst Martijn Rats upgraded Royal Dutch Shell to Equal Weight from Underweight, stating that he expects Shell to extend its guidance for capex and free cash flow beyond the current planned period to 2021 at its investor day on June 4. Additionally, he thinks Shell will announce a dividend increase after an "unprecedented" period of five years with a flat dividend. His base case assumption is that management will choose a 2c, or 4%, dividend increase and will probably also make the case that free cash flow is available to sustain this distribution. Rats has a price target of 2,490p on Shell shares.
05/09/19
MSCO
05/09/19
UPGRADE
MSCO
Equal Weight
Royal Dutch Shell upgraded to Equal Weight from Underweight at Morgan Stanley
RDS.B Royal Dutch Shell
$64.78

0.33 (0.51%)

08/31/18
08/31/18
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. BP (BP) and Royal Dutch Shell (RDS.A) were upgraded to Hold from Underperform at Santander. 2. Dollar Tree (DLTR) downgraded to Market Perform from Outperform at Telsey Advisory. 3. Electronic Arts (EA) and Activision Blizzard (ATVI) were downgraded to Neutral from Buy at BofA/Merrill. 4. Gain Capital (GCAP) initiated with a Neutral at JPMorgan. 5. Avaya (AVYA) initiated with a Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/02/19
BTIG
04/02/19
NO CHANGE
Target $225
BTIG
Buy
Wex price target raised to $225 from $198 at BTIG
BTIG analyst Mark Palmer reiterated a Buy rating on Wex (WEX) and raised his price target to $225 from $198, saying he believes the company is well positioned to deliver on the better-than-expected guidance for 2019 revenue growth that management provided on March 20 due in large part to the conversions of the Chevron (CVX) and Shell (RDS.A) fleet fuel card portfolios and the integration of recent acquisitions including the Noventis electronic payment network and Discovery Benefits.
KBH KB Home
$26.00

-0.145 (-0.55%)

05/13/19
LEHM
05/13/19
UPGRADE
Target $29
LEHM
Overweight
KB Home upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Matthew Bouley upgraded KB Home to Overweight from Equal Weight and raised his price target for the shares to $29 from $24.
05/13/19
LEHM
05/13/19
UPGRADE
Target $29
LEHM
Overweight
Barclays upgrades KB Home to Overweight on improving housing market
Barclays analyst Matthew Bouley upgraded KB Home to Overweight from Equal Weight and raised his price target for the shares to $29 from $24. The analyst says his firm's spring agent survey confirmed that housing fundamentals have improved and stabilized. Gradual market improvement links with KB Home's 2019 community ramp, allowing for accelerating growth, Bouley tells investors in a research note. This, coupled with improving margins, "manifests in more resilient returns" and should support a higher multiple, adds the analyst. He believes KB Home's valuation still reflects a market that is deteriorating.
04/10/19
JPMS
04/10/19
UPGRADE
Target $23
JPMS
Neutral
KB Home upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Michael Rehaut upgraded KB Home to Neutral from Underweight and raised his price target for the shares to $23 from $20.50. The ongoing shift towards smaller-sized first-time product and double-digit community count growth should drive "above average fundamentals" in fiscal 2019 for KB Home, Rehaut tells investors in a research note. Further, the analyst believes believe KB's "healthy relative valuation is reasonable."
04/10/19
04/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. First Solar (FSLR) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Brian Lee citing his view on two potential company-specific catalysts. 2. Disney (DIS) upgraded to Outperform from Market Perform at BMO Capital with analyst Daniel Salmon saying with tomorrow's investor day, two Star Wars-themed lands opening in the domestic parks this summer, the launch of streaming service Disney+ before year-end, and a potential re-start of the buyback program within 12 months, Disney shares now have catalysts to go along with downside protection. 3. Under Armour (UA, UAA) assumed with a Buy from Neutral at Citi with analyst Paul Lejuez saying Under Armour is "growing up" with a renewed focus on driving profitability and return on invested capital. 4. KB Home (KBH) upgraded to Neutral from Underweight at JPMorgan with analyst Michael Rehaut saying the ongoing shift towards smaller-sized first-time product and double-digit community count growth should drive "above average fundamentals" in fiscal 2019 for KB Home. 5. Nordstrom (JWN) upgraded to Overweight from Sector Weight at KeyBanc with analyst Edward Yruma saying recent meetings with co-CEO Erik Nordstrom and CFO Anne Bramman affirm that the company is prepared to transition its asset base as e-commerce continues to grow. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BDX Becton Dickinson
$224.70

-0.63 (-0.28%)

05/13/19
LEHM
05/13/19
UPGRADE
Target $266
LEHM
Overweight
Barclays upgrades Becton Dickinson to Overweight following recent pullback
Barclays analyst Kristen Stewart upgraded Becton Dickinson to Overweight from Equal Weight with an unchanged price target of $266. The pullback in the shares since the FDA update on drug-coated balloons on March 15, coupled with the resetting of expectations following the company's Q2 results, provides an opportunity for investors, Stewart tells investors in a research note. The analyst believes the reaction to the FDA update is overdone and that the upcoming FDA Committee meeting on June 19-20 is likely to provide greater clarity and calm drug-coated balloons concerns.
05/13/19
LEHM
05/13/19
UPGRADE
Target $266
LEHM
Overweight
Becton Dickinson upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Kristen Stewart upgraded Becton Dickinson to Overweight from Equal Weight with a $266 price target.
05/10/19
KEYB
05/10/19
NO CHANGE
Target $262
KEYB
Overweight
Becton Dickinson price target lowered to $262 from $273 at KeyBanc
KeyBanc analyst Matthew Mishan reiterated an Overweight rating on Becton Dickinson but lowered his price target to $262 from $273, saying investor expectations appear to have been subdued going into the Q2 report, and while it wasn't the most positive quarter or guidance update, Becton's value proposition is still mostly unchanged. Mishan tells investors in a research note that he remains comfortable with a ~5% organic growth profile, even with the paclitaxel situation and said that while the loss of the Gore Royalty will replace some of the current transitory EPS headwinds, margin expansion may be more visible in FY20.
05/13/19
WELS
05/13/19
NO CHANGE
Target $265
WELS
Outperform
Becton Dickinson price target lowered to $265 from $280 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen lowered his price target for Becton Dickinson to $265 from $280 after the company reported mixed Q2 results and maintained 2019 underlying sales growth guidance while lowering the EPS outlook. The analyst reiterates an Outperform rating on the shares.
MRK Merck
$77.21

-1.02 (-1.30%)

04/24/19
UBSW
04/24/19
NO CHANGE
Target $102
UBSW
Neutral
Procter & Gamble price target raised to $102 from $95 at UBS
UBS analyst Steven Strycula raised his price target on Procter & Gamble (PG) to $102, saying that yesterday's sell-off on investor concerns about the company's ability to boost margin "overlooks" the "upcoming inflection". The analyst keeps his Neutral rating, but notes that the Q3 margin pressure was "transitory" as it was impacted by adverse FX, commodities, higher bonus, and Merck (MRK) integration headwinds.
03/13/19
CANT
03/13/19
NO CHANGE
Target $95
CANT
Overweight
Merck opportunity in China is underappreciated, says Cantor Fitzgerald
After taking a deeper look at the Chinese PD-1 market, Cantor Fitzgerald analyst Louise Chen believes it could equate to billions of sales that are not yet in the forecasts for Merck's Keytruda. She thinks the peak sales potential of PD-1s in China remains underappreciated. China's pharma market can grow to $225B by 2025, which would support a growing PD-1/PD-L1 market, Chen tells investors in a research note titled "Deep Dive into China: A Complicated but Underappreciated Opportunity." The analyst keeps an Overweight rating on Merck with a $95 price target.
05/13/19
ATLE
05/13/19
UPGRADE
ATLE
Overweight
Merck upgraded to Overweight from Neutral at Atlantic Equities
03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).
BHC Bausch Health
$24.85

-0.45 (-1.78%)

05/07/19
MZHO
05/07/19
NO CHANGE
Target $45
MZHO
Buy
Bausch Health price target raised to $45 from $41 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Bausch Health Companies to $45 from $41 citing yesterday's "beat and raise" quarter. The analyst reiterates a Buy rating on the shares.
05/13/19
JPMS
05/13/19
UPGRADE
Target $28
JPMS
Neutral
JPMorgan upgrades Bausch Health to Neutral on 'stabilizing' EBITDA
JPMorgan analyst Chris Schott upgraded Bausch Health to Neutral from Underweight and raised his price target for the shares to $28 from $25. While a number of challenges remain in the story given the company's high leverage and controversial Xifaxan loss of exclusivity, its EBITDA is "clearly stabilizing and should begin to grow from here," Schott tells investors in a research note. The analyst's sum-of-the-parts valuation suggests little downside for Bausch Health shares.
04/26/19
JEFF
04/26/19
NO CHANGE
Target $31
JEFF
Buy
Bausch Health approval could help reaccelerate revenue, says Jefferies
Bausch Health yesterday "finally" received approval for its topical combination plaque psoriasis drug Duobrii after a protracted FDA review, Jefferies analyst David Steinberg tells investors in a research note. The analyst points out that Duobrii is the last of Bausch's "Significant 7" products to be approved from the company's late-stage dermatology pipeline. He forecasts Duobrii sales of $150M and believes the launch could help reaccelerate revenue for the company's Ortho Dermatology division post a series of loss of exclusivities. Steinberg keeps a Buy rating on Bausch Health with a $31 price target.
05/13/19
JPMS
05/13/19
UPGRADE
JPMS
Neutral
Bausch Health upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Christopher Schott upgraded Bausch Health to Neutral from Underweight.

TODAY'S FREE FLY STORIES

14:10
08/19/19
08/19
14:10
08/19/19
14:10
General news
Treasury Action: Treasuries remain heavy »

Treasury Action:…

CHE

Chemed

$434.70

4.53 (1.05%)

14:09
08/19/19
08/19
14:09
08/19/19
14:09
Hot Stocks
Chemed VP Michael Witzeman sells almost $2M in company shares »

Chemed VP Michael…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
08/19/19
08/19
14:05
08/19/19
14:05
General news
Fed's Rosengren said he believes monetary and fiscal policy are already accommodative »

Fed's Rosengren said…

AAPL

Apple

$211.93

5.49 (2.66%)

, MSFT

Microsoft

$138.27

2.14 (1.57%)

14:02
08/19/19
08/19
14:02
08/19/19
14:02
Periodicals
Microsoft hires former head of Apple's Siri efforts, The Information says »

Microsoft (MSFT) has…

AAPL

Apple

$211.93

5.49 (2.66%)

MSFT

Microsoft

$138.27

2.14 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 27

    Oct

RRR

Red Rock Resorts

$19.46

0.75 (4.01%)

, AES

AES Corp.

$15.46

0.25 (1.64%)

13:44
08/19/19
08/19
13:44
08/19/19
13:44
On The Fly
Fly Insider: Red Rock Resorts, Walgreen's among weeks notable insider trades »

Welcome to "Fly Insider,"…

RRR

Red Rock Resorts

$19.46

0.75 (4.01%)

AES

AES Corp.

$15.46

0.25 (1.64%)

GE

General Electric

$8.66

-0.13 (-1.48%)

MD

Mednax

$22.28

0.62 (2.86%)

CFR

Cullen/Frost

$85.74

0.95 (1.12%)

TWNK

Hostess Brands

$14.01

0.06 (0.43%)

WEN

Wendy's

$20.44

0.5 (2.51%)

PSA

Public Storage

$260.91

2.23 (0.86%)

AYX

Alteryx

$133.18

-0.57 (-0.43%)

WBA

Walgreens Boots Alliance

$51.40

1.3975 (2.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 03

    Sep

  • 04

    Sep

  • 09

    Sep

  • 23

    Sep

  • 02

    Oct

  • 30

    Oct

  • 13

    Nov

GIG

GigCapital

$10.30

(0.00%)

13:43
08/19/19
08/19
13:43
08/19/19
13:43
Hot Stocks
GigCapital announces launching of de-SPACing efforts of Kaleyra combination »

GigCapital announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVYA

Avaya

$12.42

-0.1 (-0.80%)

13:36
08/19/19
08/19
13:36
08/19/19
13:36
Hot Stocks
Breaking Hot Stocks news story on Avaya »

Avaya Holdings trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

RRC

Range Resources

$4.47

0.37 (9.02%)

13:35
08/19/19
08/19
13:35
08/19/19
13:35
Upgrade
Range Resources rating change  »

Range Resources rises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVYA

Avaya

$12.39

-0.13 (-1.04%)

13:33
08/19/19
08/19
13:33
08/19/19
13:33
Periodicals
Avaya said to get bid from Mitel, Bloomberg says »

Mitel, which has gone…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

AVYA

Avaya

$12.38

-0.14 (-1.12%)

13:30
08/19/19
08/19
13:30
08/19/19
13:30
Hot Stocks
Breaking Hot Stocks news story on Avaya »

Avaya Holdings trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/19/19
08/19
13:17
08/19/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/19/19
08/19
13:16
08/19/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$211.42

4.98 (2.41%)

12:51
08/19/19
08/19
12:51
08/19/19
12:51
Periodicals
Apple Arcade to likely be priced at $4.99/month, 9to5Mac reports »

Apple Arcade,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSM

Fortuna Silver Mines

$3.67

-0.01 (-0.27%)

12:48
08/19/19
08/19
12:48
08/19/19
12:48
Hot Stocks
Fortuna Silver reports fatal accident at San Jose mine »

Fortuna Silver Mines said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVRA

Savara

$2.23

0.03 (1.36%)

12:40
08/19/19
08/19
12:40
08/19/19
12:40
Conference/Events
Savara management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

G

Genpact

$41.30

0.51 (1.25%)

, FB

Facebook

$186.67

3.25 (1.77%)

12:40
08/19/19
08/19
12:40
08/19/19
12:40
Periodicals
Facebook contractor raises wages for Indian content reviewers, Reuters reports »

Genpact (G), a Facebook…

G

Genpact

$41.30

0.51 (1.25%)

FB

Facebook

$186.67

3.25 (1.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

KAR

KAR Auction

$25.67

0.18 (0.71%)

12:39
08/19/19
08/19
12:39
08/19/19
12:39
Conference/Events
KAR Auction management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 11

    Sep

  • 23

    Sep

  • 13

    Nov

ZS

Zscaler

$74.34

-6.5 (-8.04%)

12:37
08/19/19
08/19
12:37
08/19/19
12:37
Recommendations
Zscaler analyst commentary at OTR Global »

Zscaler slides after OTR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 10

    Oct

  • 15

    Oct

ENVA

Enova International

$24.92

0.31 (1.26%)

12:37
08/19/19
08/19
12:37
08/19/19
12:37
Conference/Events
Enova International management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 20

    Sep

  • 13

    Nov

AZN

AstraZeneca

$44.38

0.02 (0.05%)

12:33
08/19/19
08/19
12:33
08/19/19
12:33
Conference/Events
AstraZeneca management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 09

    Sep

  • 16

    Sep

  • 25

    Sep

  • 02

    Oct

PCG

PG&E

$10.35

-3.95 (-27.62%)

, AMGN

Amgen

$202.49

-1.46 (-0.72%)

12:22
08/19/19
08/19
12:22
08/19/19
12:22
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have been rising…

PCG

PG&E

$10.35

-3.95 (-27.62%)

AMGN

Amgen

$202.49

-1.46 (-0.72%)

PANW

Palo Alto Networks

$196.50

-2.76 (-1.39%)

WB

Weibo

$41.70

4.65 (12.55%)

DRYS

DryShips

$5.19

1.355 (35.38%)

EL

Estee Lauder

$197.80

18.54 (10.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 19

    Aug

  • 04

    Sep

  • 09

    Sep

  • 10

    Sep

  • 16

    Sep

  • 19

    Sep

  • 10

    Oct

  • 15

    Oct

LOW

Lowe's

$95.37

1.46 (1.55%)

, HD

Home Depot

$206.92

3.28 (1.61%)

12:19
08/19/19
08/19
12:19
08/19/19
12:19
On The Fly
Fly Intel: What to watch in Home Depot, Lowe's earnings reports »

Home improvement…

LOW

Lowe's

$95.37

1.46 (1.55%)

HD

Home Depot

$206.92

3.28 (1.61%)

JCP

J.C. Penney

$0.61

0.0122 (2.04%)

SHLD

Sears

$0.00

(0.00%)

AMZN

Amazon.com

$1,823.13

31.31 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 23

    Sep

  • 25

    Sep

  • 27

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
08/19/19
08/19
12:17
08/19/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,202.00

25.06 (2.13%)

, GOOGL

Alphabet Class A

$1,204.36

25.67 (2.18%)

12:16
08/19/19
08/19
12:16
08/19/19
12:16
Hot Stocks
Trump says 'Google should be sued' over role in 2016 election »

President Donald Trump…

GOOG

Alphabet

$1,202.00

25.06 (2.13%)

GOOGL

Alphabet Class A

$1,204.36

25.67 (2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
08/19/19
08/19
12:16
08/19/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.